Alessandro Loglio
A5017728788- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatitis Viruses Studies and Epidemiology
- Hepatocellular Carcinoma Treatment and Prognosis
- HIV/AIDS drug development and treatment
- Cytomegalovirus and herpesvirus research
- SARS-CoV-2 and COVID-19 Research
- Organ Transplantation Techniques and Outcomes
- Diabetes and associated disorders
- Liver Diseases and Immunity
- Immunotherapy and Immune Responses
- Systemic Lupus Erythematosus Research
- Viral Infections and Outbreaks Research
- Renal Transplantation Outcomes and Treatments
- HIV/AIDS Research and Interventions
- Diet and metabolism studies
- Cancer Immunotherapy and Biomarkers
- Alcohol Consumption and Health Effects
- Viral gastroenteritis research and epidemiology
- MicroRNA in disease regulation
- Endoplasmic Reticulum Stress and Disease
- Autophagy in Disease and Therapy
- Viral-associated cancers and disorders
Ospedale Papa Giovanni XXIII
2023-2025
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2015-2023
University of Milan
2015-2023
Ospedale Maggiore
2020-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2023
Université Claude Bernard Lyon 1
2022
National University of Health Sciences
2022
Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepatitis B patients under long‐term therapy with potent nucleos(t)ide analogues currently unclear. We therefore assessed the HCC beyond year 5 entecavir/tenofovir (ETV/TDF) and tried to determine possible factors associated late occurrence. This European, 10‐center, cohort study included 1,951 adult Caucasian without at baseline who received ETV/TDF for ≥1 year. Of them, 1,205 (62%) within first years have been...
ABSTRACT Background and Aims Management of ultrasound (US)‐guided percutaneous liver biopsy (PLB) lacks standardisation. Despite the low risk major complications (< 1%), repeated blood counts up to 4 h in‐hospital observation are typically recommended. We aimed assess complication rates predictors in a large cohort patients undergoing US‐PLB across three Italian tertiary centres. included all from January 2018 December 2023. collected clinical, biochemical procedural features (needle...
Protein induced by vitamin K absence or antagonist-II (PIVKA-II) has been suggested as a serum biomarker for hepatocellular carcinoma (HCC) in Asian hepatitis B virus (HBV)-treated subjects but no studies tested it Caucasian cirrhotics long-term nucleos(t)ide analogues (NUCs)-treated. We assessed the detection accuracy of PIVKA-II alone combination with alpha-foetoprotein (AFP) patients under surveillance.This cross-sectional, single centre case-control study was conducted 212 NUC-treated...
In chronic HBV infection, mitochondrial functions and proteostasis are dysregulated in exhausted HBV-specific CD8 T cells. To better characterise the potential involvement of deregulated protein degradation mechanisms cell exhaustion, we analysed lysosome-mediated autophagy Bioactive compounds able to simultaneously target both were tested identify optimal combination strategies reconstitute efficient antiviral responses patients with infection.Lysosome-mediated pathways by flow cytometry...
Exhausted hepatitis B virus (HBV)-specific CD8 T cells in chronic HBV infection are broadly heterogeneous. Characterisation of their functional impairment may allow to distinguish patients with different capacity control and reconstitute antiviral function.HBV dextramer+CD8 were analysed ex vivo for coexpression checkpoint/differentiation markers, transcription factors cytokines 35 HLA-A2+chronic (CHB) 29 HBsAg negative CHB who seroconverted after NUC treatment or spontaneously. Cytokine...
Summary Background An accurate, single‐point differential diagnosis between HBeAg‐negative infection (ENI) and chronic hepatitis B (CHB) is an unmet need. Aims To assess the diagnostic value of new core‐related antigen (HBcrAg) assay. Methods A retrospective anonymised data analysis was performed in a multicentre European (nine centres six countries) cohort 1582 consecutive HBsAg‐positive/HBeAg‐negative subjects classified according to EASL guidelines as: 550‐CHB, 710‐ENI 322‐GZ (grey‐zone,...
Introduction: Hepatitis D virus (HDV) infection remains a significant global health challenge due to its severity and high risk of progression cirrhosis hepatocellular carcinoma (HCC). Bulevirtide, novel HDV entry inhibitor, has shown promise in managing chronic hepatitis by blocking viral into hepatocytes. This study evaluated the efficacy safety bulevirtide reducing RNA levels improving liver function real-life cohort Italian patients with infection. Methods: multicenter prospective trial...